The partnership will expand Propeller’s presence in Europe, where Orion serves patients across several countries. Propeller’s platform currently covers more than 90 percent of inhaled medicines for asthma and COPD on the market.
Orion’s existing line of Easyhaler products will connect to Propeller’s digital medicine platform via a small, custom-built sensor. Said sensor, which is being developed collaboratively under this agreement, attaches to the inhaler and pairs with a mobile app. Propeller automatically tracks medication use and provides personal feedback and insights that help individuals and their doctors manage and reduce symptoms.
“By connecting Easyhaler to Propeller’s digital platform, we are giving our patients and their providers a new ability to improve the user experience of Easyhaler products and help patients better adhere to the treatments,” Satu Ahomäki, Orion’s Senior Vice President of Commercial Operations, said in a statement. “We are thrilled to take this step to reduce the burden of asthma and COPD via a digital companion to our medicine.”
Propeller Health is also pleased with the deal, with the company’s CEO David Van Sickle adding that the partnership with Orion is “another significant step toward reducing the burden of chronic respiratory disease for people around the world.”
Development of the new sensor will begin in 2019, with clinical trials, possible real world evidence projects and a broader commercial rollout to follow.